Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Padcev | enfortumab vedotin | Metastatic urothelial cancer | Pending | |||
| Xtandi | Enzalutamide | mHSPC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Aimovig | erenumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ajovy | fremanezumab | migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyepti | eptinezumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Botox | OnabotulinumtoxinA | Migraine | Do not list | Complete | ||
| Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | ||
| Relpax | Eletriptan hydrobromide | Migraine | Do not list | Complete | ||
| Botox | onabotulinumtoxinA | Migraine, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nurtec ODT | rimegepant | Migraine, prevention | Withdrawn |
Last Updated : April 28, 2024